Immgenuity, Inc.

FOR IMMEDIATE RELEASE

Immgenuity Inc., Announces the Appointment of Dr. Ron Sekura, BS, MS, PhD to its Scientific Advisory Board

Dover, Delaware, April 06, 2023 – Immgenuity, a biotech company focused on developing innovative immunotherapies, announced today that Dr. Ron Sekura has joined its Scientific Advisory Board.

Dr. Sekura is the former Chief of the Pharmaceutical and Regulatory Affairs Branch of the Division of AIDS at The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institute of Health (NIH), as well as a former Research Chemist at The National Institute of Child Health and Human Development (NICHD) at the NIH and the Center for Biologics Evaluation and Research (CBER). He received his Bachelor of Science and Master of Science in Biochemistry degrees at Pennsylvania State University and his PhD at Cornell University. Dr. Sekura is the author of over sixty scientific publications. Dr. Sekura is also the former President of VivoNex LLC and Biotechnology Assessment Services, Inc.

“We are delighted to welcome Dr. Sekura to our Scientific Advisory Board. His extensive expertise in regulatory affairs at the National Institutes of Health and his service as a senior scientist at the FDA’s Center for Biologics and Radiology make him an invaluable addition to our team. We look forward to working closely with him as we continue to develop our groundbreaking immunotherapy for HIV to address remission and reduction in cytokine levels”, said Dr. Sateesh Apte, CEO of Immgenuity.

“I am thrilled to join Immgenuity’s Scientific Advisory Board and to work with the company’s talented team of scientists and researchers.” Immgenuity is at the forefront of developing innovative immunotherapy solutions that have the potential to transform the way we treat HIV. I look forward to contributing my expertise and working together to achieve our shared goal of improving patient outcomes” said Dr. Sekura.

About Immgenuity, Inc.

Immgenuity, Inc. is a biotechnology company dedicated to developing innovative immunotherapy solutions to improve the lives of patients suffering from HIV. The company's lead product candidate is IMTV014, a novel immunotherapy for HIV and NeuroAIDS, which has shown to be safe in preclinical studies. Immgenuity, Inc. is headquartered in Dover, Delaware and is led by a team of experienced biotech professionals with deep expertise in infectious diseases, immunology, virology, and drug development. For more information, visit https://immgenuity.com

About IMTV014

Immgenuity's immunotherapy, IMTV014 is a genetically modified HIV virus which is unable to block immune signaling like the natural HIV does. By restoring immune signaling, IMTV014 plans to activate the immune system to create a strong, viable immune response against HIV and likely lead to clearing the virus even from the sanctuary areas where the virus persists despite aggressive anti-HIV drug treatment. IMTV014 will also address various neurological and cardiovascular comorbidities caused by the virus persistence in these anatomical sanctuary areas via prolonged and elevated secretion of inflammatory cytokines. IMTV014 also has application as "salvage therapy" in the multidrug resistant population.

Contact: Media Relations: media@immgenuity.com (302) 321-5844

Forward Looking Statements:

This press release contains "forward-looking statements" within the meaning of federal securities law, including statements concerning the company's outlook for 2023 and beyond; business strategies and their anticipated results; and similar statements concerning anticipated future events and expectations that are not historical facts. The forward-looking statements in this letter are subject to numerous risks and uncertainties, including the effects of economic conditions; supply and demand changes; competitive conditions in the industry; relationships with clients and distributors; the impact of government regulations; and the availability of capital to finance growth, which could cause actual results to differ materially from those expressed in or implied by the statements herein.